ABOUT US

NICO Corporation, formed in 2007, is an Indianapolis-based leader in modern interventional technologies used in a new way of performing less invasive brain surgery. We are an outcomes-based company dedicated to revolutionizing minimally invasive neurosurgery through a new approach using the natural folds of the brain as a path to the surgical site. The approach respects the fiber tracts and critical structures of the brain by integrating a combination of standardized technologies to achieve non-disruptive access to the surgical site with BrainPath, automated tumor removal and clot evacuation with Myriad, and intraoperative collection and preservation of all tumor tissue that may enable more precise and consistent evaluation, potentially leading to immuno-oncology and other personalized medicine options. The combination of using standardized technologies and a standardized surgical approach has resulted in 35 published papers and abstracts with evidence showing improved clinical outcomes in both tumor removal and intracerebral hemorrhage. This evidence has also earned the technology and surgical approach a place on the April 2017 cover of Neurosurgery, one of the industry’s most respected medical industry journals. NICO has been issued hundreds of patents on its technologies used in the BrainPath Approach to neurosurgery. BrainPath is FDA-cleared for use in accessing metastatic brain cancer, intracerebral hemorrhages, glioblastoma multiforme, skull base and intraventricular abnormalities. More than 5,000 BrainPath procedures and 11,000 Myriad procedures have been completed to date in the United States, Canada and now in Europe.

OUR EXECUTIVE TEAM

JIM PEARSON

Founder, President & CEO of NICO Corporation and has more than 25 years experience in health care and medical device. Named Ernst and Young’s Midwest Entrepreneur of the Year in 2007.

JOSEPH MARK

Founder and Chief Technology Officer of NICO Corporation. Develops innovative products that improve patient care and provide medical community with clinically advanced methods of tissue removal, which earned him the title of “Health Care Hero.”

JEFFREY HANTHORN

Founder, Vice President and COO of NICO Corporation and has more than 30 years of experience in healthcare, professional services, start-ups, HR and business development, including 20 years with Eli Lilly & Company.

CRAIG BLANCHARD

Vice President of Marketing & Field Clinical and has 25 years of experience in healthcare with16 years working for the combination of Guidant/Boston Scientific Corporation. Received his undergraduate Industrial Engineering Degree from Purdue University and law degree from Indiana University.

PAUL SANDEFER

Vice President of Clinical with over 25 years experience in healthcare, including Clinical Director at Suros Surgical Systems. Named NICO MVP in 2013.

PENNY SEKERAK

Vice President of Professional Education & Clinical Affairs with over 25 years experience in the hospital and healthcare industry including clinical market development and demand generation positions in medical device and diagnostic companies. Named NICO MVP in 2014.

 

KARI VENTURA

Vice President of Finance and Administration. Has over 10 years experience in pubic accounting, private equity, finance and health care.


OUR DIRECTORS

Trisha Baumgardt
Product Marketing Director, Tumor
trisha.baumgardt@niconeuro.com

Jay Dittman
Quality & Regulatory Director
jay.dittman@niconeuro.com

Craig Gaffin
Western Sales Director
craig.gaffin@niconeuro.com

Troy Gardner
Product Marketing Director, Vascular
troy.gardner@niconeuro.com

X

Inder Jarial
Engineering Director
inder.jarial@niconeuro.com

Lauren Murphy
Clinical Director
lauren.murphy@niconeuro.com

Chuck Poulsen 
Eastern Sales Director
chuck.poulsen@niconeuro.com

Jo Ellen Hansen
Director, Supply Chain
joellen.hansen@niconeuro.com

OUR BOARD OF DIRECTORS

J. Carter McNabb
Interim Chairman of the Board

Managing Director, River Cities Capital Funds
Board Member, OrthoAlign
Board Member, TissueTech
Board Member, PerfectServe, Inc.

James Baumgardt
Board Director
Former Board Chairman, NICO Corporation and Suros Surgical Systems, Inc.
Former President, Guidant NA Sales
Chairman, Guidant Foundation

Keith Brauer
Board Director
Former Board Member, Suros Surgical Systems, Inc.
Former CFO, Guidant Corporation
Former Executive, Eli Lilly and Company

Jeffrey Hanthorn
COO and Board Member
Former Vice President of HR, Sales and Operations,
Suros Surgical Systems, Inc.
Founding Partner, Revelant Technologies, LLC
20-year Executive, Eli Lilly and Company

Joseph Mark
Chief Technology Officer and Board Member
Co-Founder & Former Board Member, Suros Surgical Systems, Inc.
Board Member, SCP Limited
Co-Founder & Board Member, Promex, Inc.

X

Niles L. Noblitt
Board Member
Trustee, Rose-Hulman Institute of Technology
Former Co-Founder, Biomet, Inc.
Former Chairman of the Board, Biomet, Inc.
Former Managing Director, BioMer CV, Zwijndrecht, The Netherlands

Jim Pearson
President & CEO and Board Member
Former President & CEO, Suros Surgical Systems, Inc.
Former Board Member, Suros Surgical Systems, Inc.
Former Divisional President, Hologic, Inc.
Former President & CEO, Summit Medical

Harry Gonso
General Counsel
Senior Partner, Ice Miller, LLP

Ryan C. Kitchell
Board Observer
Executive Vice President & Chief Administrative Officer
IU Health

 

Kyle Salyers
Board Observer
Senior Vice President, Health Catalyst

MISSION STATEMENT

The mission of NICO Corporation is to revolutionize minimally invasive neurosurgical care through the creation of innovative breakthrough technologies, proper education and teamwork resulting in better clinical and economic outcomes.

NICO TECHNOLOGY & COMPANY HISTORY

NICO’s roadmap to success has been a journey of exciting challenges and achievements. Click the link below to see our milestones from 2007 to today!

CORE GUIDING PRINCIPLES

The following core guiding principles steer NICO’s research and technology:

  • Develop technology that addresses the unmet needs of the patient.
  • Develop technology that “levels the playing field” for the clinician so that as higher levels of procedural difficulty are encountered, the ability to address clinical outcomes remain reproducible and predictable.
  • Develop technology that addresses economic outcomes for the health care provider.